文献速递肝病

代谢功能障碍相关脂肪性肝病中糖RNA生物合成受损

Impaired glycoRNA biogenesis in metabolic-dysfunction associated steatotic liver disease.
PubMed 文献 · J Hepatol · 2026-06-17

本研究首次报道糖RNA存在于人肝组织、原代肝细胞和肝癌细胞,并在MASLD患者肝组织中表达降低。机制上SIDT1和DTWD2下调导致糖RNA丢失,抑制二者加重肝细胞脂质负荷和炎症信号,而AAV介导的体内恢复可减轻小鼠MASH。

要点

  • 糖RNA在人肝细胞和肝组织中合成,MASLD时表达下调。
  • SIDT1和DTWD2下调是MASLD中糖RNA丢失的关键机制。
  • 恢复糖RNA生物合成可减轻临床前模型的脂肪性肝损伤。

核心结论

  • 糖RNA存在于人肝细胞和肝组织,在MASLD中表达失调,恢复其生物合成可减轻临床前脂肪肝损伤。

研究设计与样本

  • 基础与转化研究,采用Northern blot和成像方法检测糖RNA,并在小鼠模型中通过AAV恢复关键介导因子。

主要发现

  • MASLD患者肝组织中大多数糖RNA表达降低。
  • 抑制SIDT1和DTWD2增加原代人肝细胞脂肪酸负荷并增强与巨噬细胞共培养时的炎症信号。
  • AAV介导的SIDT1和DTWD2体内恢复减轻小鼠MASH。
  • 富集糖RNA测序鉴定出8个在脂肪变性人肝和肝细胞中下调的糖RNA。

临床怎么用

  • 糖RNA表达失调提示其可能作为MASLD肝损伤的新型生物标志物。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Glycosylated proteins and lipids regulate multiple cellular processes and play key roles in organ damage and regeneration. Recently, glycosylated non-coding small RNAs (glycoRNA) have been identified, however, their expression in the liver and their involvement in hepatic pathology has not yet been reported. METHODS: We detected the presence of glycoRNAs by northern blot and an imaging approach called sialic acid aptamer and RNA in situ hybridization-mediated proximity ligation assay that enables direct visualization of glycoRNAs. Restoration of key mediators of glycoRNA biosynthesis was achieved in vivo, via adeno-associated viral vectors (AAV). RESULTS: Here, we show that glycoRNAs are synthesized in human liver tissue, primary hepatocytes and hepatic tumor cells. In tissues from patients with key features of metabolic dysfunction-associated steatotic liver diseases (MASLD), the most prevalent liver disease worldwide, expression of most glycoRNAs was reduced. Mechanistically, we found that reduced expression of SID1 transmembrane family member 1 (SIDT1) and DTW domain containing 2 (DTWD2), two key mediators of glycoRNA biosynthesis, contribute to loss of glycoRNAs in MASLD. Inhibition of SIDT1 and DTWD2 increased fatty acid load in primary human hepatocytes and enhanced inflammation signals upon co-culture with macrophages. Importantly, AAV-mediated in vivo restoration of SIDT1 and DTWD2 attenuated metabolic dysfunction-associated steatohepatitis in mice. Furthermore, sequencing of enriched glycoRNA samples identified eight glycoRNAs that were downregulated in steatotic human liver and hepatocytes. CONCLUSIONS: Collectively, our study demonstrates the presence of glycoRNAs in human hepatocytes and human liver tissues and their dysregulated expression in experimental steatosis models and in patients with MASLD. IMPACT AND IMPLICATIONS: Recent estimates suggest that up to 24% of the world's population is affected by metabolic dysfunction-associated steatotic liver diseases (MASLD). Our study reports for the first time that glycosylated RNAs (glycoRNA), a recently discovered class of RNA, are present in the liver and their expression is dysregulated in fatty liver injury. Importantly, in vivo restoration of glycoRNA biogenesis, attenuated fatty liver injury in preclinical models of MASLD. Furthermore, our results suggest that glycoRNA expression is dysregulated in human livers with MASLD, indicating their potential as novel biomarkers of liver injury.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Dong C, Zhong X, Peng Q, et al. Impaired glycoRNA biogenesis in metabolic-dysfunction associated steatotic liver disease. J Hepatol. 2026. PMID: 42309287. doi:10.1016/j.jhep.2026.04.034

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。